BioB I just laid it out above! Two posts up. My reasoning is as follows. There was support at $9.50 this was my buy zone as well because we had spoken about that big volume stick up at $10.00 and at what price would they throw in the towel we said $9.60 or so and then wait for that final washout which occurred 50 cents later. Now using psychology we can make a new level of support at $10.00 saying fast money that bought into the story late (barrons) has been washed out as well and now the first and correct trend can resume which is UP. So I would let the dust settle and get back in between $10.00 and $10.50. ~stoney
I can respect that but when i day-trade in an IRA it ties up the purchase money for T+3. And how the heck did i accumulate 5000 shares of CBLI when nobody else seemed to have heard of it? Simple. I knew the market and i knew that when the news spread, people would be willing to snap i up for a big premium over my "stealth accumulation" price of $6.09 i got by buying the dips simply for its "value" or potential momo, actually. And, sure enough, when the news hit on 1/25 at the WSJ, i had a BIG position, which gave me a $25 K gain in 2-4 months. But it didn't really take off until the 2/5 Barron's piece, even though the WSJ article had said much more and quoted Gudkov from CBLI as saying that a "cocktail" of drugs might be optimal. The WSJ was stupid in putting Chemet on a par with Neumune (HEPH) and Protectan (CBLI) because health physics MDs have been using EDTA for plutonium intakes since the 1940s, and Prussian Blue for cesium (and now thallium) intakes (at least on the TV show NCIS that showed the Tuesday night before the 2/21 peak of CBLI), since i don't know off-hand of an actual radiation accident involving thallium intake. Why did i buy 5000 shares of CBLI late last year? Because of the "value" of putting money into a undiscovered stock that was not a total fraud, because if they accept NASA and DoD GRANTS to develop a drug for the U.S. government, i KNOW that they have their books audited regularly (sometimes twice a year) by GSA, and also they could go to jail if they are indicted for defrauding the government, and prison when convicted. And they HAVE TO share ALL their data with their government sponsors as part of the SBIR contracts they received. And, rest assured, company proprietary info is safeguarded carefully by both those agencies. But misleading investors like Fonstein did at Roth with his smoke and mirrors act is a different story. Only a nuke scientist who has worked in health physics could see how he subtly only *twisted* the truth by equating an RDD (the "dirty bomb") with what nuclear weapon designers would call a low-tech "improvised" nuclear weapon which, yes, is publicly stated to have a plausible nuclear yield of 1 kT TNT-equivalent. Now, when i look at the relative exposure of the two ONLY two companies competing in this space, i see only stupidity from the dumb news-following money which is causing rallies in CBLI while HEPH languishes while they're close enough to a DoD procurement TODAY and an FDA-approved animal-efficacy rule emergency use approval for civilians by sometime this year. Where is HEPH stock price? Nowhere? Why do i hold my 2000 shares? Because good news will push it over $10 and all they need is one procurement and other countries will follow. I've traded it before when i bought it at $7 and sold it at over $10. And if US DoD buys *HEPH's* Neumune for the troops prior to FDA approval under animal-efficacy rule (DoD is exempt from FDA regulation because of their national security waiver) ... then their will be public pressure for HHS and FDA to get off their butts and buy some Neumune to protect the public from ARS under Project Bioshield ... which, unless you have a small nuke weapon (as Gudkov knows) you only need enough doses (small #) for the immediate bystanders (who were not "disassembled" by the HE blast) and, mostly, the first responders and medical personnel treating (and decontaminating) the exposed population or troops exposed in emergency cleanup for a critical facility. But once it gets the "blessing" of the US, Israel and South Korea will be placing orders pronto, and they want to protect their POPULATION from the (likely) nuke weapons of North Korea and Iran, which would mean bigger orders for Neumune than the Project Bioshield orders. But when i was accumulating CBLI below $7 late last year, the potential upside far outweighed the downside for it, which i saw as the $5 IPO price. I'm sorry for being so grouchy today. A lot of my stocks are down. I deleted that post within the 30 minutes edit time. Going by your "Buy Value, but only on strength" maxim ... which sounds a lot like Ronald Reagan's "Trust, but verify" which he said re NUCLEAR arms control agreements ... ADLR and ASEI might be interesting buys for you to keep an eye on. But i don't have the nerve to day-trade CBLI based on rallies that defy logic. I'll buy maybe if resistance trades places with support, meaning @ $7-$8 but only after a confirmation of a new (higher) trading range for CBLI ... but i think right now that a big short like Mark Cuban could totally destroy CBLI and knock it down below $5 by putting a Sell on it. BOTTOM LINE? There is nothing but hype and dumb hot air holding up this stock. And that's coming from someone who used to be one of the people who would do the calculations for the government to estimate how many people would be exposed at various levels for various scenarios.
i disagree. i think that the "correct" trend for CBLI is flat, not UP, because they're behind HEPH in a procurement, and i can't figure out a scenario where GI syndrome would dominate over bone-marrow syndrome for ARS. HEPH addresses bone-marrow syndrome. CBLI is addressing GI syndrome and the DoD wants that? I don't have the foggiest idea why that would be the case. I don't like to buy stocks which are going up based on fake hype because they can crash in a second.
bottomfeed I'm running late my wife's going to kill me she's waiting in a restaurant- limit 900n shares CBLI @ $11.50. NOW
i MIGHT start buying again only if it goes below $9.00, and would more likely be a buyer between $8.00 and $7.00 (the top of where it was trending before the breakout).
AVNR is not a Bottom Feed, it's more like a swamp, or quicksand. A diligent bottom feeder runs across a lot opf garbage in the course of a day. kind of like working in a sewer. there was some buying at the end of the day. probably mostly short covering. http://finance.yahoo.com/q/bc?s=AVNR&t=my&l=on&z=m&q=l&c= FDA wants a lower dose. sound familiar? but for AVNR it means they have 2 years to do a replay of their P2 and P3 studies and it's probably less than even odds at best that the drug will be effective there with 95% confidence.